Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says

MT Newswires Live

07/31

Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.

The company's collaboration with Sanofi (SNY) could become a "more leverageable asset" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.

A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.

The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.

Price: 736.42, Change: -1.92, Percent Change: -0.26

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2655124360"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655124360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655124360?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655124360","market":"us","top_or_hot":-1,"title":"Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.</p><p>The company's collaboration with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.</p><p>A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.</p><p>The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.</p><p>Price: 736.42, Change: -1.92, Percent Change: -0.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-31 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.</p><p>The company's collaboration with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.</p><p>A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.</p><p>The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.</p><p>Price: 736.42, Change: -1.92, Percent Change: -0.26</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655124360","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655124360","pubTimestamp":1785511282,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron Pharmaceuticals'  robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.The company's collaboration with Sanofi  could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.Price: 736.42, Change: -1.92, Percent Change: -0.26","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"加拿大皇家银行表示，再生元制药第二季度销售强劲，支出增长有限，有助于提高下半年利润率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.The company's collaboration with Sanofi (SNY) could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.Price: 736.42, Change: -1.92, Percent Change: -0.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}